Plasma d-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer

Oncology (Switzerland)

Volumn 83, Issue 1, 2012, Pages 10-15

  Yamamoto, Manabu ^a,b   Yoshinaga, Keiji ^a   Matsuyama, Ayumi ^a   Iwasa, Tokiomi ^a   Osoegawa, Atsushi ^a   Tsujita, Eiji ^a   Yamashita, Yoichi ^a   Tsutsui, Shinichi ^a   Ishida, Teruyoshi ^a  

^a ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^b Saiseikai Yahata General Hospital   (Japan)

Author keywords

Colorectal carcinoma; D dimer; Prognosis

Indexed keywords

BEVACIZUMAB; D DIMER; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; MALE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

AGED; COLORECTAL NEOPLASMS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84862506667     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000338329     Document Type: Article

References (45)

1. Nordlinger B, Guigust F, Vaillant P, Balladur P, Boudjema K, Bachellier P, Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262. (Pubitemid 26102322)
2. Aldringhetti L, Castroldi R, Di Palo S, Arru M, Stella M, Orsenigo E, Gavazzi F, Ferla G, Di Carlo V, Staudacher C: Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases. Chir Ital 2005; 57: 555-570.
3. McMillan DC, Elahi MM, Satter N, Angerson WJ, Johnstone J, McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-67.
4. McMillan DC, Canna K, McArdle CS: Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 2003; 90: 215-219. (Pubitemid 36237897)
5. Nozoe T, Matsumata T, Sugimachi K: Preoperative evaluation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 2000; 23: 263-266. (Pubitemid 32428031)
6. Shimada H, Nabeya Y, Okazaki S, Matsubara H, Shiratori T, Aoki T, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T: Evaluation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 248-252. (Pubitemid 36936011)
7. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ: C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-590. (Pubitemid 38500312)
8. Guillem P, Triboulet JP: Elevated serum protein levels of C-reactive protein are indicative of poor prognosis protein in patients with esophageal cancer. Dis Esophagus 2005; 18: 146-150. (Pubitemid 41801107)
9. Gerhardt T, Miltz S, Schepke M, Feldmann G, Wolff M, Sauerbrunch T, Dumoulin FL: C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 2006; 12: 5495-5500. (Pubitemid 44501808)
10. Canna K, McArdle PA, McMillan DC, Mc-Nicol AM, Smith GW, Mckee RF, McArdle CS: The relationship between tumour T-lymphocytes infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005; 92: 651-654. (Pubitemid 40460599)
11. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867. (Pubitemid 36019639)
12. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dagg K, Scott HR: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperative non-small cell lung cancer. Br J Cancer 2004; 90: 1704-1706. (Pubitemid 38725637)
13. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperative nonsmall-cell lung cancer. Br J Cancer 2005; 92: 1834-1836. (Pubitemid 40826128)
14. Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N: Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 2004; 48: 171-173. (Pubitemid 39045778)
15. Brown DJ, Milroy R, Preston T, McMillan DC: The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 2006; 60: 705-708. (Pubitemid 46975230)
16. Crumley AB, McMillan DC, McKernan Mc, Donald AC, Stuart RC: Evaluation of an inflammation-based prognostic score in patients with inoperative gastro-oesophageal cancer. Br J Cancer 2006; 94: 637-641. (Pubitemid 43361893)
17. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, Mckay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperative pancreatic cancer. Pancreatology 2006; 6: 450-453. (Pubitemid 44624278)
18. Read JA, Choy ST, Beale PJ, Clarke SJ: Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer 2006; 55: 78-85. (Pubitemid 44477048)
19. Ramsey S, Lamb GW, Aichison M, Graham J, McMillan DC: Evaluation of an inflammation-based prognostic score in patients with inoperative metastatic renal cancer. Cancer 2007; 109: 205-212. (Pubitemid 46106235)
20. Ishizuka M, Nagata H, Takagi K, Kubota K: Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for advanced or recurrent unresectable colorectal cancer. Ann Surg 2009; 250: 268-272.
21. Leitch EF, Chakrabarti M, Crozier JE, Mc-Kee RF, Anderson JH, Horgan PG, McMillan DC: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007; 97: 1266-1270. (Pubitemid 350035815)
22. Leung EY, Crozier JE, Talwar D, O'Reilly DS, McKee RF, Horgan PG, McMillan DC: Vitamin antioxidants, lipid peroxidation, tumour stage, the systemic inflammatory response and survival in patients with colorectal cancer. Int J Cancer 2008; 123: 2460-2464.
23. Crozier JE, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC: Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer. Am J Surg 2009; 197: 544-549.
24. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Lglehart JD, Dewhirst M, Greenberg C: Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000; 18: 600-608. (Pubitemid 30078541)
25. Mirshahi SS, Pujada-Lauraine E, Soria C, Mirshahi M, Fretault J, Bermadou A, Soria J: D-dimer and CA125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anticancer treatment. Cancer 1992; 69: 2289-2292.
26. Dirix LY, Salgado R, Weytigens R, Colpaert C, Benoy I, Huget P, van Dam P, Prove A, Lemmes J, Vermeulen P: Plasma fibrin Ddimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395. (Pubitemid 34185123)
27. Ferrigno D, Buccheri G, Ricca I: Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001; 17: 667-673. (Pubitemid 32492555)
28. Oya M, Aiyama Y, Yanagida T, Akao S, Ishikawa H: Plasma D-dimer level in patients with colorectal cancer. Surg Today 1998; 28: 373-378.
29. Edward CM, Warran J, Armstrong L, Donnelly PK: D-dimer: a useful marker of disease stage in surgery for colorectal cancer. Br J Cancer 1995; 80; 1404-1405. (Pubitemid 23345099)
30. Tomimaru Y, Yano M, Takachi Y, Kishi K, Miyashiro I, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Imamoka S: Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 2006; 202: 139-145. (Pubitemid 43000354)
31. Dirix LY, Salgado R, Colpaert C, Benoy I, Hugut I, van Dam P, Prove A, Lemmens J, Vermeulen P: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-395. (Pubitemid 34185123)
32. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Dirk lglehart J, Dewhirst M, Greenberg C: Plasma D-dimer levels in operative breast cancer patients correlate with clinical stage and axillary lymph node status. J Cin Oncol 2000; 18: 600-608. (Pubitemid 30078541)
33. Wojtsukeiwics MZ, Zacharski LR, Memoli VA, Kisiei W, Kudryk BJ, Rousseau SM, Stump DC: Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989; 64: 1062-1066. (Pubitemid 20011490)
34. Kwaan HC, Keer HN: Fibrinolysis and cancer. Semen Thrombi Heamost 1990; 16: 230-235. (Pubitemid 20289930)
35. Gouin-Thibault I, Samama MM: Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Haemost 1999; 25: 167-172. (Pubitemid 29227145)
36. Gadducci A, Baicchi U, Marrai R, Ferdeghini M, Bianchi R, Facchini V: Preoperative evaluation of D-dimer and CA125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 1996; 60: 197-202. (Pubitemid 26058762)
37. Francis CW, Marder DJ: Mechanism of fibrinolysis; in Coller B (ed.): Williams Hematology, ed. 5. McGraw-Hill, New York, 1995, pp 1252-1260.
38. Geenen RW, Delaere KP, van Werch W: Coagulation and fibrinolysis activation markers in prostatic carcinoma patients. Eur J Clin Chem Clin Biochem 1997; 35: 69-72. (Pubitemid 27129854)
39. van Duijnhoven EM, Lustermans FA, van Wersch JW: Evaluation of the coagulation/ fibrinolysis balance in patients with colorectal cancer. Haemostasis 1993; 23: 168-172. (Pubitemid 23308551)
40. Buccheri G, Ferrigno D, Ginardi C, Zuliani C: Haemostatic abnormalities in lung cancer. Prognostic implications. Eur J Cancer 1997; 33: 50-55. (Pubitemid 27099567)
41. Taguchi O, Gabazza EC, Yasue H, Kobayashi T, Yoshida M, Kobayashi H: Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997; 52: 563-565. (Pubitemid 27298511)
42. Rella C, Coviello M, Frenza ND, Falco G, Chiuri E, Colavito P, Quaranata M, De Leonardis A: Plasma D-dimer measurement as a marker of gynecological tumors: comparison with CA125. Tumori 1993; 79: 347-351. (Pubitemid 24098937)
43. Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, Koc M: Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis 2007; 10: 238-241.
44. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K: Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 2007; 246: 1047-1051. (Pubitemid 350179198)
45. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007; 22: 881-886. (Pubitemid 46952036)